{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T19:07:34Z","timestamp":1769713654539,"version":"3.49.0"},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Pulmonology"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Severe asthma (SA) in children is a complex condition with high morbidity and healthcare costs. Mepolizumab, an anti\u2010interleukin\u20105 biologic, is approved for severe eosinophilic asthma (SEA) in patients \u2265\u20096 years, yet long\u2010term real\u2010world pediatric data remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To assess the long\u2010term safety and effectiveness of mepolizumab in pediatric SEA, focusing on lung function, oral corticosteroid (OCS) use, and exacerbation rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, multicenter study examined the medical records of 33 patients with SEA (aged 6\u201317 years) who received mepolizumab treatment at three tertiary centers in Turkiye. Inclusion criteria included GINA\u2010defined SA, \u2265\u20092 severe exacerbations in the previous year requiring OCS, high\u2010dose ICS plus a second controller, and elevated eosinophil counts. Data on exacerbations, pulmonary function tests (PFTs), OCS use, ACT scores, eosinophils, and adverse events were collected over 24 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At baseline, patients showed poor asthma control (median ACT: 13), impaired lung function (FEV1%: 62%), and frequent exacerbations (median: 7\/year). Mepolizumab significantly reduced exacerbation rates (median: 7 to 0\u20130.05 at 12\/24 months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005) and OCS use (87.9% OCS\u2010free by 3 months). ACT scores improved (median: 13\u201325,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), as did FEV1% (62% to 89%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) at 24 months. Eosinophil counts decreased markedly (460 to 50 cells\/\u00b5L,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The treatment was well\u2010tolerated; one patient discontinued due to anaphylaxis and four due to lack of efficacy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Mepolizumab showed sustained effectiveness and good tolerability in pediatric SEA, significantly reducing exacerbations and OCS use while improving asthma control and lung function. These findings support its real\u2010world utility and underscore the need for careful patient selection and monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ppul.71466","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T09:09:23Z","timestamp":1768208963000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real\u2010World Effectiveness and Safety of Mepolizumab in Pediatric Severe Eosinophilic Asthma: A Multicenter Study"],"prefix":"10.1002","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0621-4312","authenticated-orcid":false,"given":"Nadira Nabiyeva","family":"\u00c7evik","sequence":"first","affiliation":[{"name":"Department of Pediatric Allergy Hacettepe University, Faculty of Medicine Ankara T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7841-4690","authenticated-orcid":false,"given":"Melike","family":"Ocak","sequence":"additional","affiliation":[{"name":"Department of Pediatric Allergy Hacettepe University, Faculty of Medicine Ankara T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaye","family":"Kocatepe","sequence":"additional","affiliation":[{"name":"Department of Pediatric Allergy and Immunology Akdeniz University Antalya T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilg\u00fcn Bahar","family":"Teker","sequence":"additional","affiliation":[{"name":"Department of Pediatric Allergy Cukurova University, Faculty of Medicine Adana T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilara Fatma","family":"Kocacik Uygun","sequence":"additional","affiliation":[{"name":"Department of Pediatric Allergy and Immunology Akdeniz University Antalya T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahir","family":"Serbes","sequence":"additional","affiliation":[{"name":"Department of Pediatric Allergy Cukurova University, Faculty of Medicine Adana T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilek","family":"Ozcan","sequence":"additional","affiliation":[{"name":"Department of Pediatric Allergy Cukurova University, Faculty of Medicine Adana T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0886-3332","authenticated-orcid":false,"given":"Aysen","family":"Bingol","sequence":"additional","affiliation":[{"name":"Department of Pediatric Allergy and Immunology Akdeniz University Antalya T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4232-3396","authenticated-orcid":false,"given":"Bulent Enis","family":"Sekerel","sequence":"additional","affiliation":[{"name":"Department of Pediatric Allergy Hacettepe University, Faculty of Medicine Ankara T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-0412"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-62264-9"},{"key":"e_1_2_11_4_1","doi-asserted-by":"crossref","unstructured":"The Global Asthma Report 2022 International Journal of Tuberculosis and Lung Disease: The Official Journal of the International Union against Tuberculosis and Lung Disease26 no.Supp 1(2022):1\u2013104.","DOI":"10.5588\/ijtld.22.1010"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.5152\/TurkThoracJ.2019.19025"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21346"},{"issue":"4","key":"e_1_2_11_7_1","first-page":"280","article-title":"Extent and Burden of Allergic Diseases in Elementary Schoolchildren: A National Multicenter Study","volume":"20","author":"Civelek E.","year":"2010","journal-title":"Journal of Investigational Allergology & Clinical Immunology"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3038.2008.00769.x"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000512"},{"key":"e_1_2_11_10_1","unstructured":"American Lung Association \u201cTrends in Asthma Morbidity and Mortality\u201d (2012) http:\/\/www.lung.org\/finding-cures\/our-research\/trend-reports\/asthma-trend-report.pdf."},{"key":"e_1_2_11_11_1","unstructured":"\u201cPopulation Demography Housing and Gender Statistics\u201d and \u201cNational Accounts Statistics \u201dhttps:\/\/www.Turkstat.Gov.Tr\/."},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3038.2008.00739.x"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/pai.13007"},{"key":"e_1_2_11_14_1","unstructured":"Gsk.Nucala Prescribing Information.2023. [accessed june 22 2023] https:\/\/www.Accessdata.Fda.Gov\/drugsatfda_docs\/label\/2023\/125526orig1s021 761122orig1s011corrected_lbl.Pdf."},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.07.007"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.09.033"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15056"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30125-X"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15382"},{"key":"e_1_2_11_20_1","unstructured":"Global Strategy for Asthma Management and Prevention: Gina Main Repor. (2024).https:\/\/ginasthma.Org\/2024-report\/."},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9970-z"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-012-0309-1"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01198-9"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.005"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.920066"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291"}],"container-title":["Pediatric Pulmonology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ppul.71466","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ppul.71466","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ppul.71466","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T08:27:21Z","timestamp":1769675241000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ppul.71466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/ppul.71466"],"URL":"https:\/\/doi.org\/10.1002\/ppul.71466","archive":["Portico"],"relation":{},"ISSN":["8755-6863","1099-0496"],"issn-type":[{"value":"8755-6863","type":"print"},{"value":"1099-0496","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-07-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71466"}}